Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 3:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: United States Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Fit for Duty: mHealth Intervention for Weight Gain Prevention

NCT06110273
View directory record Official record
Conditions
Obesity
Interventions
Fit for Duty-mobile, m-Health Control
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 39 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 28, 2026, 3:27 AM EDT
Terminated Phase 3 Interventional

Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients

NCT00004986
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Nitazoxanide
Drug
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 3:27 AM EDT
Completed Phase 3 Interventional

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

NCT02032277
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Cyclophosphamide, Placebo, Doxorubicin, Paclitaxel, Carboplatin, Veliparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
61
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 28, 2026, 3:27 AM EDT
Terminated No phase listed Observational Results available

Understanding Hemophilia A and B Drug Dosage Administration Patterns

NCT03248141
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Hemophilia B standard half-life, Hemophilia B extended half-life, Hemophilia A standard half-life, Hemophilia A extended half-life
Drug
Lead sponsor
Pfizer
Industry
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Gainesville, Florida • Las Vegas, Nevada • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2019 · Synced Sep 28, 2026, 3:27 AM EDT
Withdrawn Not applicable Interventional

Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops

NCT01306266
View directory record Official record
Conditions
Chronic Post-traumatic Headache
Interventions
Rizatriptan, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 49 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Sep 28, 2026, 3:27 AM EDT
Recruiting Phase 4 Interventional

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections

NCT06738407
View directory record Official record
Conditions
Gonorrhea, Chlamydia, Syphilis, Sexually Transmitted Infections (STIs)
Interventions
Doxycycline hyclate delayed released 200 mg, Doxycycline hyclate delayed released 200 mg weekly, Per standard of care with quarterly STI testing/treatment and sexual health counseling
Drug · Other
Lead sponsor
Westat
Other
Eligibility
13 Years to 29 Years · Female only
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 28, 2026, 3:27 AM EDT
Recruiting Phase 2 Interventional

Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure

NCT07131475
View directory record Official record
Conditions
Blast Injury
Interventions
PBR28 TSPO PET
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 28, 2026, 3:27 AM EDT
Completed Phase 2 Interventional

Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins

NCT03198793
View directory record Official record
Conditions
Hypertension
Interventions
QGC001
Drug
Lead sponsor
Quantum Genomics SA
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 28, 2026, 3:27 AM EDT
Completed Phase 1 Interventional

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

NCT02920398
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Torrance, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Sep 28, 2026, 3:27 AM EDT
Completed No phase listed Observational

Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i

NCT06975371
View directory record Official record
Conditions
Advanced/Metastatic HER2-negative Breast Cancer
Interventions
No drug
Other
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 28, 2026, 3:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adjuvanted Influenza Vaccination Year 2 Follow-On Survey

NCT03599739
View directory record Official record
Conditions
Influenza, Influenza-like Illness, Influenza, Human
Interventions
Influenza
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Sep 28, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen

NCT00764322
View directory record Official record
Conditions
Breast Cancer, Menopausal Symptoms
Interventions
tamoxifen citrate, gene expression analysis, pharmacogenomic studies, questionnaire administration, quality-of-life assessment
Drug · Genetic · Other + 1 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 28, 2026, 3:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

NCT06130345
View directory record Official record
Conditions
SARS-CoV-2
Interventions
SPIKEVAX
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
Not listed
Enrollment
15,196,685 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 28, 2026, 3:27 AM EDT
Active, not recruiting No phase listed Observational

A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)

NCT02951598
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Florbetapir F 18 PET Scan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
77
States / cities
Anaheim, California • Imperial, California • Irvine, California + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 28, 2026, 3:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

NCT05514509
View directory record Official record
Conditions
HIV Infections
Interventions
APRETUDE, Cabotegravir tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
370 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
22
States / cities
Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 28, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Tularemia Vaccine Comparison

NCT01150695
View directory record Official record
Conditions
Tularaemia
Interventions
Placebo, Undiluted Francisella tularensis live attenuated vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
5
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Sep 28, 2026, 3:27 AM EDT
Completed No phase listed Observational

eVusheld Assessment reaL wORld Effectiveness in the VA Health System

NCT05663957
View directory record Official record
Conditions
SARS-CoV-2, COVID-19
Interventions
Evusheld
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
5,814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 28, 2026, 3:27 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks

NCT05012189
View directory record Official record
Conditions
Influenza, Influenza, Human, Influenza -Like Illness
Interventions
Oseltamivir, Baloxavir
Drug
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
18 Years to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 28, 2026, 3:27 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement

NCT01240902
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
1,453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 28, 2026, 3:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Single Doses of IV Aerucin in Healthy Adults

NCT02486770
View directory record Official record
Conditions
Healthy
Interventions
Aerucin 2.0mg/kg, Aerucin 8.0mg/kg, Aerucin 20.0 mg/kg
Biological
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Sep 28, 2026, 3:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.

NCT01154296
View directory record Official record
Conditions
HIV/AIDS, Sexually Transmitted Infections
Interventions
RESPECT-2 Counseling
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
5,012 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Sep 28, 2026, 3:27 AM EDT
Completed No phase listed Observational

Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States

NCT03197688
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Notapplicable
Other
Lead sponsor
Actelion
Industry
Eligibility
Not listed
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
105
States / cities
Phoenix, Arizona • La Jolla, California • Loma Linda, California + 89 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 28, 2026, 3:27 AM EDT
Completed Phase 4 Interventional

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

NCT00847483
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
40
States / cities
Bellflower, California • Inglewood, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 28, 2026, 3:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Refugee Family Strengthening (RFS) Program

NCT02829086
View directory record Official record
Conditions
Health Behavior
Interventions
Relationship Enhancement, Family Stress and Conflict Management, Financial Management
Other
Lead sponsor
US Committee for Refugees and Immigrants
Other
Eligibility
16 Years and older
Enrollment
5,365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Des Moines, Iowa • Dearborn, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Sep 28, 2026, 3:27 AM EDT